Jefferies Financial Group reiterated their buy rating on shares of Haleon (LON:HLN – Free Report) in a research note issued to investors on Friday morning,Digital Look reports. They currently have a GBX 400 price target on the stock.
Several other equities analysts have also weighed in on HLN. Royal Bank Of Canada reissued a “sector perform” rating and issued a GBX 370 target price on shares of Haleon in a research note on Thursday, April 30th. Deutsche Bank Aktiengesellschaft reaffirmed a “sell” rating and issued a GBX 325 price target on shares of Haleon in a research note on Wednesday, July 1st. JPMorgan Chase & Co. cut their price target on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Finally, Berenberg Bank reissued a “buy” rating and set a GBX 512 price objective on shares of Haleon in a research note on Thursday, April 30th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of GBX 395.33.
Read Our Latest Stock Analysis on Haleon
Haleon Stock Performance
Haleon (LON:HLN – Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a return on equity of 10.30% and a net margin of 15.11%. Equities research analysts forecast that Haleon will post 19.5033282 EPS for the current year.
Haleon Company Profile
Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.
Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.
Recommended Stories
- Five stocks we like better than Haleon
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Haleon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haleon and related companies with MarketBeat.com's FREE daily email newsletter.
